Previous 10 | Next 10 |
Increase in revenue of $166.9 million observed with FDA approved DMD drugs in Q3 of 2021; year over year increase of 37%. Next-generation PPMO drugs are being advanced in order to improve upon the first generation types; in addition, other mutations observed in DMD are being targeted ...
- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced muscle tropism and microdystrophin expression - - Company enters 2022 with a...
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will p...
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice Presiden...
If you’re looking for the best penny stocks to buy now, you might be looking at different trends. Whether they be industry trends or something more thematic, there’s no shortage of attention-grabbing catalysts. In the stock market today, everything from electric vehicles to en...
If you’re looking for different themes in the stock market today, the “short squeeze” has grown in popularity. It’s been a topic we’ve discussed for a few months related explicitly to penny stocks. But it has taken on a life of its own, even with higher-pr...
Solid Biosciences (NASDAQ:SLDB): Q3 Net Loss of $18M beats by $18.20. Collaboration Revenue of $3.5M beats by $2.18M. Press Release Cash, cash equivalents and available-for-sale securities of $229.8M as of September 30, 2021. For further details see: Solid Biosciences EPS...
- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene therapy program demonstrates enhanced muscle tropism and microdystrophin expres...
The Pathway Development Consortium (PDC), a new public-private collaboration by Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB), announced the publication of Draft Framework for AAV Gene Therapy Development. The draft white paper proposes a framework that can be applied ...
- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development Consortium is building a collaboration of patients, industry, regulators, academia...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...